Thomas Doyle - Jan 2, 2024 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Signature
Teresa Bair, Attorney-in-fact for Thomas Doyle
Stock symbol
KURA
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 04:08 PM
Previous filing
Feb 21, 2023
Next filing
Jan 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +21.3K +72.87% $0.00 50.4K Jan 2, 2024 Direct F1, F2
holding KURA Common Stock 500 Jan 2, 2024 spouse's 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KURA Option to purchase common stock Award $0 +42.5K $0.00 42.5K Jan 2, 2024 Common Stock 42.5K $15.36 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/25, 1/26/26, 1/26/27 and 1/26/28.
F2 Includes 1,489 shares acquired on May 17, 2023 and 206 shares acquired on November 17, 2023 pursuant to the Issuer's Employee Stock Purchase Plan.
F3 This option vests in 48 equal monthly installments commencing on the grant date.